RxDoctor Payments DataLook up a doctor →

Brett Bennett, MD

Interventional Cardiology · Jackson, MSNPI 1538471842

Payments from drug & device makers

$560,918in general payments, 2019–2025

Across 1,136 payments — averaging $493.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • CSL Behring$145K
  • Abbott$133K
  • Boston Scientific$77K
  • Medtronic$66K
  • Amgen$54K
  • Boehringer Ingelheim International GmbH$31K
  • plus $54K from 47 others

What the payments were for

  • Consulting fees$7,5006%
  • Speaking & faculty fees$61,77549%
  • Travel & lodging$30,42424%
  • Food & beverage$25,86321%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$560,918 in reported general payments places this provider in the 95th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$1,125,361
Medicare patients
1,790
Services billed
21,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban806$564,523
EntrestoSacubitril/Valsartan504$415,008
BrilintaTicagrelor259$128,260
FarxigaDapagliflozin Propanediol138$95,910
XareltoRivaroxaban96$95,726
Repatha SureclickEvolocumab69$52,450
JardianceEmpagliflozin50$30,336
Metoprolol Succinate658$6,884
Atorvastatin Calcium683$4,486
ClopidogrelClopidogrel Bisulfate600$4,260
Ranolazine ErRanolazine46$3,036
EdarbyclorAzilsartan Med/Chlorthalidone12$2,950
Flecainide Acetate62$2,922
Carvedilol480$2,743
Rosuvastatin Calcium326$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$221$564,523806 claims
NovartisEntresto$2,018$415,008504 claims
AstraZenecaBrilinta, Farxiga$556$224,170397 claims
Johnson & JohnsonXarelto$460$95,72696 claims
Boehringer IngelheimJardiance$604$30,33650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →